RxDoctor Payments Data

Antoinette Berkeley Gsegnet, MD

Urology · Cortlandt Manor, NYNPI 1720092224

Payments from drug & device makers

$1,477in general payments, 2019–2025

Across 44 payments — averaging $33.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$276
  • Pfizer$184
  • E.r. Squibb & Sons, L.L.C.$125
  • Novo Nordisk$125
  • AbbVie$124
  • Biohaven Pharmaceutical Holding Company Ltd.$103
  • plus $540 from 13 others

What the payments were for

  • Food & beverage$1,46399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,477 in reported general payments places this provider in the 40th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$197,662
Medicare patients
512
Services billed
3,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron175$202,351
GemtesaVibegron22$27,270
Lupron DepotLeuprolide Acetate11$26,047
ElmironPentosan Polysulfate Sodium17$19,514
Mirabegron ErMirabegron18$15,086
Tamsulosin Hcl521$11,305
Oxybutynin Chloride ErOxybutynin Chloride273$8,358
Finasteride320$5,683
Fesoterodine Fumarate ErFesoterodine Fumarate25$4,107
Silodosin27$3,914
Potassium Citrate ErPotassium Citrate15$3,515
Tolterodine Tartrate ErTolterodine Tartrate25$3,110
Alfuzosin Hcl ErAlfuzosin Hcl53$1,361
Desmopressin Acetate14$1,339
Dutasteride35$1,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$276$202,351175 claims
Sumitomo Pharma America, Inc.Gemtesa$26$27,27022 claims
AbbVieLupron Depot$124$26,04711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 952 urology providers in New York.

Other urology in Cortlandt Manor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →